Patients submitted for consideration for treatment with GS010/Lumevoq must meet specific eligibility criteria, including the length of time since the onset of their vision loss.

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

News » DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies ...

Studienergebnisse DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies 23.12.2025 / 14:36 CET/CEST ...

This article explores limitations of chemical synthesis in high-throughput settings and the technical advantages enzymatic ...

Seasoned Biotech Entrepreneur Dr. Christian Thirion Appointed CEO of DiNATEQ AG and Group Chief Strategy & Business Development Officer; Dr. Josef El Andari Named Chief Scientific Officer of DiNAQOR ...

Francesca Vitelli and Orla Cloak from Minaris with Matthew Durdy, Eytan Abraham, and Dan Gibson of CGT Catapult.

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over 2 years old.

We used to assume bird flu was a risk solely for outdoor hunters, but new data suggests the virus is entering the home ...